
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is expected to release its first clinical product, TVGN 489, which is initially focused on treating COVID-19 in high-risk populations, but also has potential applications in treating chronic symptoms of the disease (Long COVID). Additionally, the company's potential acquisition of a contract research organization could improve earnings visibility and support a more efficient growth strategy. However, there are risks to consider, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks.
Bears say
Tevogen Bio Holdings is facing multiple risk factors, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. With potential dilution risk due to a large decrease in stock price and pushing back the timeline for commercialization to 2029, it is understandable that the financial analyst has a negative outlook and has lowered the price target to $2.0 from $5.0. In addition, the company has a high accumulated deficit and operating losses, indicating potential financial instability in the future, despite efforts to improve cost efficiency.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares